Trial Profile
A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms RUSTYS
- Sponsors Biogen Idec
- 22 May 2014 New trial record